Opinion|Videos|December 8, 2025
Concluding Thoughts: Practical Tips, Resources, and More
Author(s)Jonathan M. Meyer, MD, DLFAPA
Summarizing key messages and reinforce the value of TDM in improving patient outcomes.
Advertisement
This video covers the following questions:
- If you could leave psychiatrists with 3 key takeaways about clozapine TDM, what would they be?
- How do you envision the role of TDM evolving as we move toward more personalized and precision-based psychiatry?
- Any final advice for clinicians looking to optimize clozapine treatment through better use of monitoring tools and data?
Advertisement
Related to this article
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Should Postpartum Psychosis Be Included in the DSM?
4
Blinding, Ethics, and Safety Safeguards in Psychedelic Clinical Research
5